A COMPARATIVE STUDY OF LONG-TERM OUTCOMES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) AND ASTHMA PATIENTS RECEIVING INHALED CORTICOSTEROIDS
DOI:
https://doi.org/10.54112/bcsrj.v2024i1.1478Keywords:
Chronic Obstructive Pulmonary Disease, Asthma, Inhaled Corticosteroids, Lung Function, ExacerbationsAbstract
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in most industrialized countries and affects about three million people worldwide. Objective: The primary objective of this study is to compare the long-term outcomes in patients with chronic obstructive pulmonary disease (COPD) and asthma who receive inhaled corticosteroids. Objective: To compare the long-term outcomes of inhaled corticosteroid (ICS) therapy in patients with chronic obstructive pulmonary disease (COPD) and asthma. Methods: This comparative, observational study was conducted at the Department of Pulmonology, Pak Emirates Military Hospital, a tertiary care center, from July 2024 to October 2024. A total of 230 patients participated in the study. Results: Data were collected from 230 patients. Asthma patients were younger (47.89 ± 12.02 years) compared to COPD patients (55.01 ± 10.23 years, p < 0.001) and had a higher proportion of females (70% vs. 30%, p < 0.001). Smoking history was more prevalent in COPD patients (85% vs. 10%, p < 0.001), reflecting its role as a primary risk factor. Asthma patients had a higher baseline BMI (25.5 ± 3.2 kg/m² vs. 23.8 ± 4.1 kg/m², p = 0.02) and shorter disease duration (8 ± 3 years vs. 12 ± 4 years, p < 0.01). Additionally, asthma patients had better baseline lung function (FEV1 68 ± 8% vs. 58 ± 10%, p < 0.001) and lower exacerbation rates (2.1 ± 0.5 vs. 3.2 ± 0.6 events/year, p < 0.001). The mean FEV1 improvement in asthma patients was 15% ± 3%, compared to 7% ± 2% in COPD patients (p = 0.01). Similarly, the FEV1/FVC ratio improved more in asthma patients (+12%) than in COPD patients (+5%, p = 0.01). Conclusion: It is concluded that inhaled corticosteroid (ICS) therapy significantly improves long-term outcomes in both asthma and Chronic Obstructive Pulmonary Disease (COPD) patients, but its effects are more pronounced in asthma.
Downloads
References
Mkorombindo, T., & Dransfield, M. T. (2020). Inhaled corticosteroids in COPD: Benefits and risks. Clinics in Chest Medicine, 41(3), 475. https://doi.org/10.1016/j.ccm.2020.05.006
Melani AS, Croce S, Fabbri G, Messina M, Bargagli E. Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History. Biomolecules. 2024 Feb 6; 14(2):195. Doi: 10.3390/biom14020195. PMID: 38397432; PMCID: PMC10887366.
Yang I.A., Ferry O.R., Clarke M.S., Sim E.H., Fong K.M. Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.. 2023; 3:CD002991. Doi: 10.1002/14651858.CD002991.pub4.
Wedzicha J.A., Banerji D., Chapman K.R., Vestbo J., Roche N., Ayers R.T., Thach C., Fogel R., Patalano F., Vogelmeier C.F., et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N. Engl. J. Med. 2016; 374:2222–2234. Doi: 10.1056/NEJMoa1516385.
Halpin D.M.G., Worsley S., Ismaila A.S., Beeh K.M., Midwinter D., Kocks J.W.H., Irving E., Marin J.M., Martin N., Tabberer M., et al. INTREPID: Single-versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res. 2021; 7:00950-2020. Doi: 10.1183/23120541.00950-2020.
Alcázar-Navarrete B., Jamart L., Sánchez-Covisa J., Juárez M., Graefenhain R., Sicras-Mainar A. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients with COPD Treated with Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain. Chest. 2022; 162:1017–1029. Doi: 10.1016/j.chest.2022.06.033.
Halpin D.M.G., Rothnie K.J., Banks V., Czira A., Compton C., Wood R., Tritton T., Massey O., Wild R., Snowise N., et al. Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. Int. J. Chron. Obstruct. Pulmon. Dis. 2022; 17:2417 2429. Doi: 10.2147/COPD.S370540.
Deslee G., Fabry-Vendrand C., Poccardi N., Thabut G., Eteve Pitsaer C., Coriat A., Renaudat C., Maguire A., Pinto T. Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: A retrospective study on THIN database BMJ Open Respir. Res. 2023; 10:e001585. Doi: 10.1136/bmjresp-2022-001585.
Lipson D.A., Barnhart F., Brealey N., Brooks J., Criner G.J., Day N.C., Dransfield M.T., Halpin D.M.G., Han M.K., Jones C.E., et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N. Engl. J. Med. 2018; 378:1671–1680. Doi: 10.1056/NEJMoa1713901.
Rabe K.F., Martinez F.J., Ferguson G.T., Wang C., Singh D., Wedzicha J.A., Trivedi R., St Rose E., Ballal S., McLaren J., et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N. Engl. J. Med. 2020; 383:35–48. Doi: 10.1056/NEJMoa1916046.
Martinez F.J., Rabe K.F., Ferguson G.T., Wedzicha J.A., Singh D., Wang C., Rossman K., St Rose E., Trivedi R., Ballal S., et al. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am. J. Respir. Crit. Care Med. 2021; 203:553 564. Doi: 10.1164/rccm.202006-2618OC.
Calverley P.M.A., Anderson J.A., Celli B. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356:775–789. Doi: 10.1056/NEJMoa063070.
Lipson D.A., Crim C., Criner G.J., Day N.C., Dransfield M.T., Halpin D.M.G., Han M.K., Jones C.E., Kilbride S., Lange P., et al. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2020; 201:1508–1516. doi: 10.1164/rccm.201911-2207OC
Suissa S. Triple therapy in COPD: Understanding the data. ERJ Open Res. 2023; 9:00615–02022. Doi: 10.1183/23120541.00615-2022.
Dransfield M.T., Kunisaki K.M., Strand M.J., Anzueto A., Bhatt S.P., Bowler R.P., Criner G.J., Curtis J.L., Hanania N.A., Nath H., et al. COPDGene Investigators. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2017; 195:324–330. Doi: 10.1164/rccm.201605-1014OC.
Whittaker H., Rubino A., Müllerová H., Morris T., Varghese P., Xu Y., De Nigris E., Quint J.K. Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. Int. J. Chronic Obstr. Pulm. Dis. 2022; 17:427–437. Doi: 10.2147/COPD.S346591.
Vestbo J., Fabbri L., Papi A., Petruzzelli S., Scuri M., Guasconi A., Vezzoli S., Singh D. Inhaled corticosteroid containing combinations and mortality in COPD. Eur. Respir. J. 2018; 52:1801230. Doi: 10.1183/13993003.01230-2018.
Singh D., Agusti A., Martinez F.J., Papi A., Pavord I.D., Wedzicha J.A., Vogelmeier C.F., Halpin D.M.G. Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. Am. J. Respir. Crit. Care Med. 2022; 206:17–24. Doi: 10.1164/rccm.202201-0209PP.
Adcock I.M., Bhatt S.P., Balkissoon R., Wise R.A. The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice. Am. J. Med. 2022; 135:302–312. doi: 10.1016/j.amjmed.2021.09.006
Hersh C.P. Pharmacogenomics of chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2019; 13:459–470. doi: 10.1080/17476348.2019.1601559.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 RI KHAN, SA SATTI , IN SHEEN , AU AFRIDI, K ALI, A KHALIQ
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
